Personality disorders do not affect treatment outcomes for chronic HCV infection in Spanish prisoners: the Perseo study

Andrés Marco, José J Antón, Joan Trujols, Pablo Saíz de la Hoya, José de Juan, Inmaculada Faraco, Joan A Caylà, Perseo Group, C Alia, F Amaya, J M Antolin, J Borrego, E Campo, A da Silva, J R Díaz, J Domingo, C Gallego, J García-Guerrero, A M Herrero, G Jiménez-Galan, J M Laine, E Leandro, C López, R Muros, F Paniagua, J Pérez de los Cobos, A Pérez-Valenzuela, R Planella, E Pozo, J R Rebolledo, P Sánchez-Arrobas, C Sarriera, C Solé, L C Vasallo, M Veiras, C Yllobre, J Zúñiga, Andrés Marco, José J Antón, Joan Trujols, Pablo Saíz de la Hoya, José de Juan, Inmaculada Faraco, Joan A Caylà, Perseo Group, C Alia, F Amaya, J M Antolin, J Borrego, E Campo, A da Silva, J R Díaz, J Domingo, C Gallego, J García-Guerrero, A M Herrero, G Jiménez-Galan, J M Laine, E Leandro, C López, R Muros, F Paniagua, J Pérez de los Cobos, A Pérez-Valenzuela, R Planella, E Pozo, J R Rebolledo, P Sánchez-Arrobas, C Sarriera, C Solé, L C Vasallo, M Veiras, C Yllobre, J Zúñiga

Abstract

Background: The link between infection with hepatitis C virus (HCV) and personality disorders (PD) has not been investigated in detail. The aim of this study was to compare the effectiveness of HCV treatment in prisoners with and without PD.

Methods: We performed a prospective multicentre study in inmates from 25 Spanish prisons who had been treated with pegylated interferon alfa-2a plus ribavirin in 2011. PD diagnosis was based on the Personality Diagnostic Questionnaire-4+. We calculated adjusted Odds Ratios (AOR) and 95 % confidence intervals (95 % CI) using logistic regression.

Results: The sample included 236 patients (mean age: 40.3 years, 92.8 % male, 79.2 % intravenous drug users, and 26.3 % HIV-coinfected). The prevalence of PD was 72.5 %. 32.2 % of patients discontinued treatment; this percentage was higher in patients with HCV genotypes 1/4 (AOR = 3.55; CI:1.76-7.18) and those without PD (AOR = 2.51; 1.23-5.11). Treatment discontinuation was mainly for penitentiary reasons (40.3 %): release or transfer between prisons. The rate of sustained viral response (SVR) was 52.1 % by ITT and 76.9 % by observed treatment (OT). SVR was higher among patients with genotype 2 or 3, and those with low baseline HCV-RNA. We did not observe any differences between individuals with and without PD in term of SVR, HCV genotype or HIV infection.

Conclusions: Our results support the safety and clinical effectiveness of the treatment of chronic HCV infection in correctional facilities, both in prisoners with PD and those without. Our data support non-discrimination between patients with and without PD when offering treatment for HCV infection to prison inmates.

Trial registration: Trial registration number (TRN) NCT01900886 . Date of registration: July 8, 2013.

Figures

Fig. 1
Fig. 1
Summary of patient selection process. *Depending on the score obtained on any of the validity scales. PDQ-4+: Personality Diagnostic Questionnaire-4+; PD: personality disorders; CSS: clinical significance scale; SRQ: self-reported questionnaire
Fig. 2
Fig. 2
Treatment discontinuation in prisoners with and without personality disorders, stratified by cause of treatment interruption. *Release and/or transfer between prisons. PD: personality disorder; NS: not significant

References

    1. Schaefer M, Sarkar R, Diez-Quevedo C. Management of mental health problems prior to and during treatment of hepatitis C virus infection in patients with drug addiction. Clin Infect Dis. 2013;57(Suppl 2):S111–7. doi: 10.1093/cid/cit266.
    1. Schaefer M, Capuron L, Friebe A, Diez-Quevedo C, Robaeys G, Neri S, et al. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol. 2012;57:1379–90. doi: 10.1016/j.jhep.2012.07.037.
    1. Spaulding AC, Weinbaum CM, Lau DT, Sterling R, Seeff LB, Margolis HS, et al. A framework for management of hepatitis C in prisons. Ann Intern Med. 2006;144:762–9. doi: 10.7326/0003-4819-144-10-200605160-00010.
    1. Saíz de la Hoya P, Marco A, García-Guerrero J, Rivera A. Prevalhep study group. Hepatitis C and B prevalence in Spanish prisons. Eur J Clin Microbiol Infect Dis. 2011;30:857–62. doi: 10.1007/s10096-011-1166-5.
    1. Fazel S, Danesh J. Serious mental disorder in 23000 prisoners: a systematic review of 62 surveys. Lancet. 2002;359:545–50. doi: 10.1016/S0140-6736(02)07740-1.
    1. Marco Mouriño A, Antón Basanta JJ, Saíz de la Hoya P, de Juan Ramírez J, Faraco I, Perseo Group Prevalence of personality disorder in Spanish penitentiary population. Subanalysis of Perseo study. J Hepatol. 2013;58(Suppl 1):S320–1. doi: 10.1016/S0168-8278(13)60789-8.
    1. American Psychiatric Association . iagnostic and Statistical Manual of Mental Disorders, 4th ed., text rev. 4. Washington, DC: American Psychiatric Association; 2000.
    1. Scheft H, Fontenette DC. Psychiatric barriers to readiness for treatment for hepatitis C Virus (HCV) infection among injection drug users: clinical experience of an addiction psychiatrist in the HIV-HCV coinfection clinic of a public health hospital. Clin Infect Dis. 2005;40(Suppl 5):S292–6. doi: 10.1086/427443.
    1. Hopley AA, Brunelle C. Personality mediators of psychopathy and substance dependence in male offenders. Addict Behav. 2012;37:947–55. doi: 10.1016/j.addbeh.2012.03.031.
    1. Schaefer M, Hinzpeter A, Mohmand A, Janssen G, Pich M, Schwaiger M, et al. Hepatitis C treatment in “difficult-to-treat” psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology. 2007;46:991–8. doi: 10.1002/hep.21791.
    1. Calvo Piñero N, Caseras Vives X. Gutiérrez Ponce de León F, Torrubia Beltri R. Spanish version of the Personality Diagnostic Questionnaire-4+ (PDQ-4+) Actas Esp Psiquiatr. 2002;30:7–13.
    1. Calvo N, Gutiérrez F, Casas M. Diagnostic agreement between the Personality Diagnostic Questionnaire-4+ (PDQ-4+) and its Clinical Significance Scale. Psicothema. 2013;25:427–32.
    1. Fonseca-Pedrero E, Paino M, Lemos-Giráldez S, Muñiz J. Maladaptative personality traits in adolescence: Psychometric properties of the Personality Diagnostic Questionnaire-4+ Int J Clin Health Psychol. 2013;13:207–15. doi: 10.1016/S1697-2600(13)70025-5.
    1. Calvo N, Gutiérrez F, Andión O, Caseras X, Torrubia R, Casas M. Psychometric properties of the Spanish version of the self-report Personality Diagnostic Questionnaire −4+ (PDQ-4+) in psychiatric outpatients. Psicothema. 2012;24:156–60.
    1. Abdin E, Koh KG, Subramaniam M, Guo ME, Leo T, Teo C, et al. Validity of the Personality Diagnostic Questionnaire-4 (PDQ-4+) among mentally ill prison inmates in Singapore. J Pers Disord. 2011;25:834–41. doi: 10.1521/pedi.2011.25.6.834.
    1. Davison S, Leese M, Taylor PJ. Examination of the screening properties of the personality diagnostic questionnaire 4+ (PDQ-4+) in a prison population. J Pers Disord. 2001;15:180–94. doi: 10.1521/pedi.15.2.180.19212.
    1. Greeven PG, De Ruiter C. Personality disorders in a Dutch forensic psychiatric sample: changes with treatment. Crim Behav Ment Health. 2004;14:280–90. doi: 10.1002/cbm.594.
    1. Yovtcheva SP, Rifai MA, Moles JK, Van der Linden BJ. Psychiatric comorbidity among hepatitis C-positive patients. Psychosomatics. 2001;42:411–5. doi: 10.1176/appi.psy.42.5.411.
    1. Fernández-Montalvo J, Echeburúa E. Trastornos de personalidad y psicopatía en hombres condenados por violencia grave contra la pareja. Psicothema. 2008;20:193–8.
    1. Vicens E, Tort V, Dueñas RM, Muro Á, Pérez-Arnau F, Arroyo JM, et al. The prevalence of mental disorders in Spanish prisons. Crim Behav Ment Health. 2011;21:321–32. doi: 10.1002/cbm.815.
    1. Boonwaat L, Haber PS, Levy MH, Lloyd AR. Establishment of a successful assessment and treatment service for Australian prison inmates with chronic hepatitis C. Med J Aust. 2010;192:496–500.
    1. Maru DS, Bruce RD, Basu S, Altice FL. Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations. Clin Infect Dis. 2008;47:952–61. doi: 10.1086/591707.
    1. Rice JP, Burnett D, Tsotsis H, Lindstrom MJ, Cornett DD, Voermans P, et al. Comparison of Hepatitis C Virus Treatment Between Incarcerated and Community Patients. Hepatology. 2012;56:1252–60. doi: 10.1002/hep.25770.
    1. Strock P, Mossong J, Hawotte K, Arendt V. Access to treatment of hepatitis C in prison inmates. Dig Dis Sci. 2009;54:1325–30. doi: 10.1007/s10620-008-0483-8.
    1. Chew KW, Allen SA, Taylor LE, Rich JD, Feller E. Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C. J Clin Gastroenterol. 2009;43:686–91. doi: 10.1097/MCG.0b013e31818dd94c.
    1. Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med. 2003;138:187–90. doi: 10.7326/0003-4819-138-3-200302040-00010.
    1. Iacomi F, Iannicelli G, Franceschini A, Migliorisi P, Rosati S, Piselli P, et al. HCV infected prisoners: should they be still considered a difficult to treat population? BMC Infect Dis. 2013;13:374. doi: 10.1186/1471-2334-13-374.
    1. Lloyd AR, Clegg J, Lange J, Stevenson A, Post JJ, Lloyd D, et al. Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting. Clin Infect Dis. 2013;56:1078–84. doi: 10.1093/cid/cis1202.
    1. Farley JD, Wong VK, Chung HV, Lim E, Walters G, Farley TA, et al. Treatment of chronic hepatitis C in Canadian prison inmates. Can J Gastroenterol. 2005;19:153–6.
    1. de Juan J, Saíz de la Hoya P, Marco A, Antón JJ, Faraco I, Yllobre C, et al. Multicenter study on the discontinuation and efficacy of chronic hepatitis C treatment in the Spanish penitentiary population (EPIBAND Study) Eur J Gastroenterol Hepatol. 2014;26:1083–9. doi: 10.1097/MEG.0000000000000163.
    1. Saiz de la Hoya P, Portilla J, Marco A, Garcia-Guerrero J, Faraco I, Antón JJ, et al. Directly obseved therapy for chronic hepatitis C: A randomized clinical trial in the prison setting. Gastroenterol Hepatol. 2014;37:443–51. doi: 10.1016/j.gastrohep.2014.03.004.
    1. Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis. 2013;57(suppl):S80–9. doi: 10.1093/cid/cit306.
    1. Searson G, Engelson ES, Carriero D, Kotler DP. Treatment of chronic hepatitis C virus infection in the United States: some remaining obstacles. Liver Int. 2014;34:668–71. doi: 10.1111/liv.12467.
    1. Bruggmann P. Accessing Hepatitis C patients who are difficult to reach: it is time to overcome barriers. Viral Hepat. 2012;19:829–35. doi: 10.1111/jvh.12008.
    1. Spennati A, Pariante CM. Withdrawing interferon-α from psychiatric patients: clinical care or unjustifiable stigma? Psychol Med. 2013;43:1127–32. doi: 10.1017/S0033291712001808.
    1. Schaeffer M, Sarkar R, Díez-Quevedo C. Management of mental health problems prior to and during treatment of hepatitis C virus infection in patients with drug addiction. Clin Infecrt Dis. 2013;57(suppl):S111–7. doi: 10.1093/cid/cit266.
    1. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry. 2000;157:867–76. doi: 10.1176/appi.ajp.157.6.867.
    1. Schaefer M, Engelbrecht MA, Gut O, Fiebich BL, Bauer J, Schmidt F, et al. Interferon alpha (IFNalpha) and psychiatric syndromes: a review. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:731–46. doi: 10.1016/S0278-5846(01)00324-4.
    1. Sockalingam S, Links PS, Abbey SE. Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update. J Viral Hepat. 2011;18:153–60. doi: 10.1111/j.1365-2893.2010.01393.x.
    1. Leutscher PD, Lagging M, Buhl MR, Pedersen C, Norkrans G, Langeland N, et al. Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology. 2010;52:430–5. doi: 10.1002/hep.23699.
    1. Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry. 2005;66:41–8. doi: 10.4088/JCP.v66n0106.
    1. Schafer A, Wittchen HU, Seufert J, Kraus MR. Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C – a critical review. Int J Methods Psychiatr Res. 2007;16:186–201. doi: 10.1002/mpr.229.
    1. Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, et al. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study. J Gastroenterol Hepatol. 2012;27:1233–40. doi: 10.1111/j.1440-1746.2011.06965.x.
    1. Kelly EM, Corace K, Emery J, Cooper CL. Bipolar patients can safely and successfully receive interferon-based hepatitis C antiviral treatment. Eur J Gastroenterol Hepatol. 2012;24:811–6. doi: 10.1097/MEG.0b013e3283535c56.
    1. Mustafa MZ, Schofield J, Mills PR, Priest M, Fox R, Datta S, et al. The efficacy and safety of treating hepatitis C in patients with a diagnosis of schizophrenia. J Viral Hepat. 2014
    1. Huckans M, Mitchell A, Ruimy S, Loftis J, Hauser P. Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia. Schizophr Bull. 2010;36:165–72. doi: 10.1093/schbul/sbn065.
    1. Carrión JA, Gonzalez-Colominas E, García-Retortillo M, Cañete N, Cirera I, Coll S, et al. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C. J Hepatol. 2013;59:926–33. doi: 10.1016/j.jhep.2013.06.019.
    1. Sublette VA, Douglas MW, McCaffery K, George J, Perry KN. Psychological, lifestyle and social predictors of hepatitis C treatment response: a systematic review. Liver Int. 2013;33:894–903. doi: 10.1111/liv.12138.
    1. Council of Europe. Annual penal statistics “Space II”. Strasbourg, 29 April 2014.. [Access May 13, 2014].
    1. Marco A, da Silva A, Ortiz J, Solé C, Roget M, Sarriera C, et al. Factores predictivos de cumplimiento del tratamiento de la hepatitis C crónica en personas drogodependientes de cuatro prisiones de Barcelona, Spain. Rev Esp Salud Publica. 2010;84:424–31.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel